Table 2 Conservancy analysis of high-risk HPV L2 protein.

From: In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine

Protein Regions

Sequence and degree of conservancy

11–41 (Type 16)

KRASATQLYKTCKQAGTCPPDIIPKVEGKTI

16

18

31

33

35

39

45

51

52

56

58

59

68

100.00%

80.00%

76.67%

83.33%

86.67%

76.67%

80.00%

76.67%

83.33%

73.33%

73.33%

73.33%

73.33%

10–40 (Type 18)

KRASVTDLYKTCKQSGTCPPDVVPKVEGTTL

16

18

31

33

35

39

45

51

52

56

58

59

68

80.00%

100.0%

76.67%

76.67%

76.67%

90.00%

86.67%

83.33%

83.33%

73.33%

83.33%

83.33%

86.67%

96–120 (Type 16)

DPVGPSDPSIVSLVEETSFIDAGAP

16

18

31

33

35

39

45

51

52

56

58

59

68

100.00%

60.0%

76.00%

80.00%

76.00%

64.00%

64.00%

48.00%

64.00%

64.00%

80.00%

68.00%

60.00%

94–118 (Type 18)

EPVGPTDPSIVTLIEDSSVVTSGAP

16

18

31

33

35

39

45

51

52

56

58

59

68

60.00%

100.0%

64.0%

56.00%

52.0%

76.00%

92.00%

52.00%

56.00%

76.00%

60.00%

92.00%

80.00%

54–76 (Type 16)

FFGGLGIGTGSGTGGRTGYIPLG

16

18

31

33

35

39

45

51

52

56

58

59

68

100.00%

95.65%

86.96%

86.96%

86.67%

91.30%

86.96%

91.30%

78.26%

78.26%

95.65%

95.65%

91.30%

53–75 (Type 18)

FLGGLGIGTGSGTGGRTGYIPLG

16

18

31

33

35

39

45

51

52

56

58

59

68

95.65%

100.0%

82.61%

82.61%

82.61%

95.65%

91.30%

95.65%

73.91%

73.91%

91.30%

100.0%

67.86%

278–305 (Type 16)

APDPDFLDIVALHRPALTSRRTGIRYSR

16

18

31

33

35

39

45

51

52

56

58

59

68

100.00%

67.86%

85.71%

78.57%

82.14%

78.57%

64.29%

78.57%

82.14%

75.00%

89.29%

75.00%

82.14%

271–298 (Type 18)

VPDSDFMDIIRLHRPALTSRRGTVRFSR

16

18

31

33

35

39

45

51

52

56

58

59

68

67.86%

100.0%

78.57%

78.57%

78.57%

82.14%

96.43%

85.71%

85.71%

71.43%

78.57%

89.29%

85.71%

Back to article page